期刊文献+

VEGF165-tPA双基因真核表达载体的构建和体外表达 被引量:2

Construction and in vitro Expression of Human Vascular Endothelial Growth Factor 165 and Tissue-type Plasminogen Activator Gene Recombinant Eukaryotic Expression Vector
下载PDF
导出
摘要 目的构建人血管内皮细胞生长因子165(VEGF165)和人组织型纤溶酶原激活因子(tPA)双基因的新型真核表达载体pIRES-VEGF165-tPA,并通过转染人脐静脉内皮细胞系EA.hy926细胞,验证载体的体外表达情况。方法将目的基因片段VEGF165和tPA插入到真核表达载体pIRES质粒中,体外瞬时转染人脐静脉内皮细胞系EA.hy926细胞,通过实时荧光定量RT-PCR和Western blot分别检测mRNA和蛋白水平的表达。结果成功构建pIRES-VEGF165-tPA双基因真核表达载体,测序结果与预期相符;荧光计数显示体外瞬时转染人脐静脉内皮细胞系EA.hy926细胞的转染效率约为(15.6±3.1)%;实时荧光定量RT-PCR和Western blot证实转染pIRES-VEGF165-tPA质粒组细胞在mRNA和蛋白水平的表达均高于各对照组(均P<0.01)。结论成功构建pIRES-VEGF165-tPA双基因真核表达载体,并且实现其在人脐静脉内皮细胞系EA.hy926细胞中的表达,为进一步探索其在机械瓣膜抗凝方面的作用奠定了基础。 Objective To construct a recombinant eukaryotic expression vector pIRES-VEGF165-tPA containing functional region of human vascular endothelial growth factor 165(VEGF165)and tissue-type plasminogen activator(tPA)gene,and investigate their in vitro expression in transfected human umbilical vein endothelial cells(EA.hy926).Methods The human VEGF165 and tPA genes were inserted into the eukaryotic expression vector pIRES to construct the recombinant plasmid that was transfected into human umbilical vein endothelial cells(EA.hy926)subsequently.The transcription and expression of VEGF165 and tPA genes were detected by real-time fluorescent quantitative RT-PCR and Western blot respectively.Results The sequencing of pIRES-VEGF165-tPA approved that the genes of VEGF165 and tPA were inserted into the eukaryotic expression vector correctly.The transfection efficiency was about(15.6±3.1)%,detected by counting the positive cells of green fluorescence.The mRNA and protein expression levels of VEGF165 and tPA in the pIRES-VEGF165-tPA transfected group were significantly higher than those in the control groups(P0.01).Conclusion The recombinant eukaryotic expression vector pIRES-VEGF165-tPA is successfully constructed and can be expressed in transfected EA.hy926 cells,which lay a foundation for the subsequent study of its anticoagulant function in patients with mechanical heart valves.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2011年第1期55-59,共5页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金 国家自然科学基金资助项目(No.30872543)
关键词 人血管内皮细胞生长因子165 人组织型纤溶酶原激活因子 真核表达载体 体外表达 human vascular endothelial growth factor 165 tissue-type plasminogen activator eukaryotic expression vector gene expression in vitro
  • 相关文献

参考文献1

二级参考文献10

  • 1Sun Y,Jin K,Childs JT,et al.Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration[].Developmental Biology.2006
  • 2Carmeliet P.Blood vessels and nerves: common signals, pathways and diseases[].Nature Reviews Genetics.2003
  • 3Zhang SC,Wering M,Duncan ID,et al.In vitro differentiation of transplantable neural precursors from human embryonic stem cells[].Nature Biotechnology.2001
  • 4Maurer M H,Tripps W K,Feldmann R E Jr,et al.Expression of vascular endothelial growth factor and its receptors in rat neural stem cells[].Neuroscience Letters.2003
  • 5Galli R,Pagano SF,Gritti A,et al.Regulation of neuronal differentiation in human CNS stem cell progeny by leukemia inhibitory factor[].Developmental Neuropsychology.2000
  • 6Namiecinska M,Marciniak K,Nowak JZ.[VEGF as an angiogenic, neurotrophic, and neuroprotective factor][].Postepy Hig Med Dosw (Online).2005
  • 7Anderson L,Caldwell MA.Human neural progenitor cell transplants into the subthalamic nucleus lead to functional recovery in a rat model of Parkinson‘s disease[].Neurobiology of Disease.2007
  • 8Lambrechts D,,Carmeliet P.VEGF at the neurovascular interface: Therapeutic implications for motor neuron disease[].Biochimica et Biophysica Acta.2006
  • 9Zachary I.Neuroprotective role of vascular endothelial growth factor:signaling mechanisms,biological function,and therapeutic potential[].Neuro Signals.2005
  • 10Brusselmans K,Bono F,Collen D,et al.A novel role for vascularendothelial growth factor as an autocrine survival factor for embryonicstem cells during hypoxia[].Journal of Biological Chemistry.2005

共引文献2

同被引文献25

  • 1陈辉,张伶,朱旦,周义文,邹琳,涂植光.地尔硫卓对肾性高血压大鼠左室心肌重构的影响[J].第四军医大学学报,2005,26(7):594-598. 被引量:3
  • 2Rhee R Y, Gloviczki P, Mendonca C T, et al. Mesenteric ve- nous thrombosis:still a lethal disease in the 1990[J]. J Vasc Surg, 1994,20(5) : 688-697.
  • 3Brunaud L, Antunes L, Adler S C, et al. Acute mesenteric ve- nous thrombosis:Case for nonoperative management [J] J Vas Surg,2001,34(4) :673-679.
  • 4Aeosta S, Alhadad A, Svensson P, et al. Epidemiology, risk a nd prognostic factors in mesenteric venous thrombosis[J]. Br J Surg,2008,95(10) :1245-1251.
  • 5Acosta S. Epidemiology of mesenteric vascular disease : clinical implications[J]. Semin Vasc Surg, 2010,23 (1) : 4-8.
  • 6Safieddine N, Mamazza J,Common A,et al. Splenic and supe- rior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis[J]. Can J Surg, 2007, 50(1):68-69.
  • 7Wang M Q,Guo L P,Lin H Y,et al. Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal andsuperior mesenteric vein thrombosis[J]. Cardiovasc Intervent Radiol,2010,33(1) :80-89.
  • 8Dentali F, Ageno W, Witt D, et al. Natural history of mesen- teric venous thrombosis in patients treated with vitamin K an- tagonists., a multi-centre, retrospective cohort study [J] Thromb Haemost, 2009,102(3) :501-504.
  • 9Righini M,Perrier A,De Moerloose P, et al. D-Dimer for ve- nous thromboembolism diagnosis: 20 years later[J]. J Thromb Haemost,2008,6(7) :1059-1071.
  • 10Palareti G, Cosmi B, Legnani C, et al. I-dimer testing to de- termine the duration of anticoagulation therpy[J]. N Engl J Med,2006,355(17) :1780-1789.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部